Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | CHUK | O15111 | 5/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9578379 | 0.88 | IKBKB (0.81) | IKBKBKDM4EGFERKMT2ARXFP1 | |
| SCHEMBL3794862 | 0.85 | IKBKB (0.76) | IKBKBKDM4EGFERKMT2ARXFP1 | |
| SCHEMBL620233 | 0.84 | RECQL (0.59) | IKBKBKDM4EGFERKMT2ARECQL | |
| SCHEMBL5303404 | 0.83 | IKBKB (0.73) | IKBKBKDM4EGFERKMT2ARXFP1 | |
| SCHEMBL3781950 | 0.83 | IKBKB (1.00) | IKBKBKDM4EGFERKMT2ARXFP1 | |
| Hydrochloric Acid SCHEMBL8012538 | 0.82 | RECQL (0.58) | IKBKBKDM4EGFERKMT2ARECQL | |
| SCHEMBL5302317 | 0.81 | CHUK (0.67) | IKBKBCHUKCASP1MAP4K4ALOX5 | |
| SCHEMBL5308529 | 0.81 | IKBKB (0.71) | IKBKBKDM4EGFERKMT2ARXFP1 | |
| SCHEMBL10713802 | 0.81 | KMT2A (0.84) | IKBKBKDM4EGFERKMT2ARXFP1 | |
| SCHEMBL5306999 | 0.80 | CHUK (0.70) | IKBKBKDM4EGFERKMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213506-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12053443-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-113209066-B | Amino-aryl-benzamide compounds and methods of use thereof | 上海赫普化医药技术有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4234536-A2 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Hepanova, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3619193-B1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA INC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2021-11-04 | — | — | US | disclosed |
| CN-113209066-A | Amino-aryl-benzamide compounds and methods of use thereof | 上海赫普化医药技术有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-108785292-B | Amino-aryl-benzamide compounds and methods of use thereof | 上海赫普化医药技术有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3619193-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Hepanova, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018204775-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180318240-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2007025575-A1 | O-HYDROXY- AND O-AMINO BENZAMIDE DERIVATIVES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025575-A1 | O-HYDROXY- AND O-AMINO BENZAMIDE DERIVATIVES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213506-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | IKBKB 1103/4885KDM4E 787/4885GFER 974/4885 |
| US-20180318240-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | IKBKB 1103/4885KDM4E 787/4885GFER 974/4885 |
| US-12053443-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | IKBKB 1103/4885KDM4E 787/4885GFER 974/4885 |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | IKBKB 1103/4885KDM4E 787/4885GFER 974/4885 |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | IKBKB 1103/4885KDM4E 787/4885GFER 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.